Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise
- 1 November 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 16 (11) , 2193-2203
- https://doi.org/10.1158/1055-9965.epi-06-0942
Abstract
Prostate cancer (CaP) is second only to lung cancer as the cause of cancer-related deaths in American men and is responsible for over 29,000 deaths per year. One promising approach to reduce the incidence of CaP is through chemoprevention, which has been recognized as a plausible and cost-effective approach to reduce cancer morbidity and mortality by inhibiting precancerous events before the occurrence of clinical disease. Indeed, CaP is an ideal candidate disease for chemoprevention because it is typically diagnosed in the elderly population with a relatively slower rate of growth and progression, and therefore, even a modest delay in the development of cancer, achieved through pharmacologic or nutritional intervention, could result in substantial reduction in the incidence of clinically detectable disease. In this review, we have summarized the recent investigations and mechanistic studies on CaP chemoprevention using dietary agents, such as selenium, vitamins D and E, lycopene, phytoestrogens, flavonoids, and green tea polyphenols. Well-designed trials are required to delineate the potential clinical usefulness of these agents through issues, such as determining the optimal period and route of administration, systemic bioavailability, optimal dosing and toxicity of the agent, and single or combinatorial approach. It is hoped that, combining the knowledge based on agents with targets, effective approaches for CaP chemoprevention can be established. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2193–204)Keywords
This publication has 92 references indexed in Scilit:
- UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States)Cancer Causes & Control, 2006
- Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)The Prostate, 2006
- Prostate cancer chemoprevention by silibinin: Bench to bedsideMolecular Carcinogenesis, 2006
- Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementationThe Prostate, 2005
- THE MODULATION OF PROSTATE CANCER RISK WITH α-TOCOPHEROL: A PILOT RANDOMIZED, CONTROLLED CLINICAL TRIALJournal of Urology, 2005
- Epigallocatechin-3-O-gallate disrupts stress fibers and the contractile ring by reducing myosin regulatory light chain phosphorylation mediated through the target molecule 67kDa laminin receptorBiochemical and Biophysical Research Communications, 2005
- A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancerBJU International, 2005
- Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostateThe FASEB Journal, 2004
- Antioxidants Block Prostate Cancer in Lady Transgenic MiceCancer Research, 2004
- Selective-Inhibition of Steroid 5 α-Reductase Isozymes by Tea Epicatechin-3-Gallate and Epigallocatechin-3-GallateBiochemical and Biophysical Research Communications, 1995